MovDisordV3, PascalFrancis, Corpus, bibRecord, 002B34

Apomorphine : An underutilized therapy for Parkinson's disease

Identifieur interne : 002B34 ( PascalFrancis/Corpus ); précédent : 002B33; suivant : 002B35

Apomorphine : An underutilized therapy for Parkinson's disease

Auteurs : Werner Poewe ; Gregor K. Wenning

Source :

Movement disorders [ 0885-3185 ] ; 2000.

RBID : Pascal:00-0481439

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Apomorphine, Chimiothérapie, Agoniste, Récepteur dopaminergique, Stimulant dopaminergique, Voie souscutanée, Dyskinésie, Antiparkinsonien, Toxicité, Traitement, Indication, Complication, Homme, Fluctuation motrice.

English descriptors

KwdEn :
- Agonist, Antiparkinson agent, Chemotherapy, Complication, Dopamine agonist, Dopamine receptor, Dyskinesia, Human, Indication, Parkinson disease, Subcutaneous administration, Toxicity, Treatment.

Abstract

Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopainduced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 15`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Apomorphine : An underutilized therapy for Parkinson's disease`
A11	`01`	`1`		`@1 POEWE (Werner)`
A11	`02`	`1`		`@1 WENNING (Gregor K.)`
A14	`01`			`@1 Department of Neurology, University Hospital Innsbruck @2 Innsbruck @3 AUT @Z 1 aut. @Z 2 aut.`
A20				`@1 789-794`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000091356830040`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 58 ref.`
A47	`01`	`1`		`@0 00-0481439`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopainduced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Apomorphine @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`04`	`X`	`FRE`	`@0 Agoniste @5 06`
C03	`04`	`X`	`ENG`	`@0 Agonist @5 06`
C03	`04`	`X`	`SPA`	`@0 Agonista @5 06`
C03	`05`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 07`
C03	`05`	`X`	`ENG`	`@0 Dopamine receptor @5 07`
C03	`05`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 07`
C03	`06`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 08`
C03	`06`	`X`	`ENG`	`@0 Dopamine agonist @5 08`
C03	`06`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 08`
C03	`07`	`X`	`FRE`	`@0 Voie souscutanée @5 09`
C03	`07`	`X`	`ENG`	`@0 Subcutaneous administration @5 09`
C03	`07`	`X`	`SPA`	`@0 Vía subcutánea @5 09`
C03	`08`	`X`	`FRE`	`@0 Dyskinésie @5 10`
C03	`08`	`X`	`ENG`	`@0 Dyskinesia @5 10`
C03	`08`	`X`	`SPA`	`@0 Disquinesia @5 10`
C03	`09`	`X`	`FRE`	`@0 Antiparkinsonien @5 13`
C03	`09`	`X`	`ENG`	`@0 Antiparkinson agent @5 13`
C03	`09`	`X`	`SPA`	`@0 Antiparkinsoniano @5 13`
C03	`10`	`X`	`FRE`	`@0 Toxicité @5 16`
C03	`10`	`X`	`ENG`	`@0 Toxicity @5 16`
C03	`10`	`X`	`SPA`	`@0 Toxicidad @5 16`
C03	`11`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`11`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`11`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`12`	`X`	`FRE`	`@0 Indication @5 18`
C03	`12`	`X`	`ENG`	`@0 Indication @5 18`
C03	`12`	`X`	`SPA`	`@0 Indicación @5 18`
C03	`13`	`X`	`FRE`	`@0 Complication @5 19`
C03	`13`	`X`	`ENG`	`@0 Complication @5 19`
C03	`13`	`X`	`SPA`	`@0 Complicación @5 19`
C03	`14`	`X`	`FRE`	`@0 Homme @5 20`
C03	`14`	`X`	`ENG`	`@0 Human @5 20`
C03	`14`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`15`	`X`	`FRE`	`@0 Fluctuation motrice @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 62`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 62`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 62`
C07	`07`	`X`	`FRE`	`@0 Mouvement involontaire @5 63`
C07	`07`	`X`	`ENG`	`@0 Involuntary movement @5 63`
C07	`07`	`X`	`SPA`	`@0 Movimiento involuntario @5 63`
N21				`@1 318`

Format Inist (serveur)

NO :	PASCAL 00-0481439 INIST
ET :	Apomorphine : An underutilized therapy for Parkinson's disease
AU :	POEWE (Werner); WENNING (Gregor K.)
AF :	Department of Neurology, University Hospital Innsbruck/Innsbruck/Autriche (1 aut., 2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 5; Pp. 789-794; Bibl. 58 ref.
LA :	Anglais
EA :	Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopainduced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.
CC :	002B02B06
FD :	Parkinson maladie; Apomorphine; Chimiothérapie; Agoniste; Récepteur dopaminergique; Stimulant dopaminergique; Voie souscutanée; Dyskinésie; Antiparkinsonien; Toxicité; Traitement; Indication; Complication; Homme; Fluctuation motrice
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire
ED :	Parkinson disease; Chemotherapy; Agonist; Dopamine receptor; Dopamine agonist; Subcutaneous administration; Dyskinesia; Antiparkinson agent; Toxicity; Treatment; Indication; Complication; Human
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement
SD :	Parkinson enfermedad; Quimioterapia; Agonista; Receptor dopaminérgico; Estimulante dopaminérgico; Vía subcutánea; Disquinesia; Antiparkinsoniano; Toxicidad; Tratamiento; Indicación; Complicación; Hombre
LO :	INIST-20953.354000091356830040
ID :	00-0481439

Links to Exploration step

Pascal:00-0481439

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Apomorphine : An underutilized therapy for Parkinson's disease</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Hospital Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Hospital Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0481439</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0481439 INIST</idno>
<idno type="RBID">Pascal:00-0481439</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002B34</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Apomorphine : An underutilized therapy for Parkinson's disease</title>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Hospital Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, University Hospital Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Complication</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Dyskinesia</term>
<term>Human</term>
<term>Indication</term>
<term>Parkinson disease</term>
<term>Subcutaneous administration</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Apomorphine</term>
<term>Chimiothérapie</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Stimulant dopaminergique</term>
<term>Voie souscutanée</term>
<term>Dyskinésie</term>
<term>Antiparkinsonien</term>
<term>Toxicité</term>
<term>Traitement</term>
<term>Indication</term>
<term>Complication</term>
<term>Homme</term>
<term>Fluctuation motrice</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopainduced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Apomorphine : An underutilized therapy for Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>POEWE (Werner)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WENNING (Gregor K.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, University Hospital Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>789-794</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000091356830040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>58 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0481439</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopainduced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Agonist</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Agonista</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Voie souscutanée</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Subcutaneous administration</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Vía subcutánea</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Indication</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Indication</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Indicación</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Complication</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Complication</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Complicación</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Fluctuation motrice</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>62</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>62</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>62</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>63</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>63</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>63</s5>
</fC07>
<fN21><s1>318</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 00-0481439 INIST</NO>
<ET>Apomorphine : An underutilized therapy for Parkinson's disease</ET>
<AU>POEWE (Werner); WENNING (Gregor K.)</AU>
<AF>Department of Neurology, University Hospital Innsbruck/Innsbruck/Autriche (1 aut., 2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 5; Pp. 789-794; Bibl. 58 ref.</SO>
<LA>Anglais</LA>
<EA>Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease. While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study. A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings. Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopainduced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.</EA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Apomorphine; Chimiothérapie; Agoniste; Récepteur dopaminergique; Stimulant dopaminergique; Voie souscutanée; Dyskinésie; Antiparkinsonien; Toxicité; Traitement; Indication; Complication; Homme; Fluctuation motrice</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique; Mouvement involontaire</FG>
<ED>Parkinson disease; Chemotherapy; Agonist; Dopamine receptor; Dopamine agonist; Subcutaneous administration; Dyskinesia; Antiparkinson agent; Toxicity; Treatment; Indication; Complication; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder; Involuntary movement</EG>
<SD>Parkinson enfermedad; Quimioterapia; Agonista; Receptor dopaminérgico; Estimulante dopaminérgico; Vía subcutánea; Disquinesia; Antiparkinsoniano; Toxicidad; Tratamiento; Indicación; Complicación; Hombre</SD>
<LO>INIST-20953.354000091356830040</LO>
<ID>00-0481439</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B34 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002B34 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:00-0481439
   |texte=   Apomorphine : An underutilized therapy for Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Apomorphine : An underutilized therapy for Parkinson's disease

Apomorphine : An underutilized therapy for Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri